Invivyd Reports Q3 2026 Financial Results and Updates on VYD2311
Invivyd posted Q3 2026 net product revenue of $15.4 million and updated the regulatory timeline for its COVID-19 antibody VYD2311. While investing in commercial preparedness, the company faces revenue headwinds due to the expiration of PEMGARDA's EUA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed